HbA1c
EstablishedHbA1c is the central biomarker for diagnosing and monitoring diabetes, reflecting average blood glucose over 2-3 months.
HbA1c shows average blood sugar over the past few months, making it the single most important number for diagnosing and managing diabetes. It can be misleading in people with certain blood conditions that affect how long red blood cells survive, since the test depends on that survival time.
Hemoglobin A1c (HbA1c) reflects average blood glucose over the preceding 2-3 months, based on the proportion of hemoglobin that has become glycated (sugar-bound); it is the central biomarker for diagnosing and monitoring diabetes mellitus.
HbA1c ≥6.5% supports a diabetes diagnosis, 5.7-6.4% indicates prediabetes, and treatment targets (typically <7% for most adults with diabetes, individualized based on age and comorbidities) guide ongoing management decisions across essentially all diabetes care.
Measured via immunoassay or high-performance liquid chromatography (HPLC); results can be unreliable in conditions affecting red blood cell lifespan (hemolytic anemia, recent transfusion, certain hemoglobinopathies), where HbA1c may run falsely low or high regardless of true average glucose.
HbA1c results directly guide medication intensification or de-escalation decisions and are checked roughly every 3-6 months in diabetes management; current guidelines increasingly emphasize individualized targets, with looser goals appropriate for older adults or those with limited life expectancy where tight control's risks may outweigh benefits.
Unreliable in conditions affecting red blood cell lifespan; current guidelines favor individualized rather than universal targets.
- General endocrinology reference literature on HbA1c in diabetes diagnosis, monitoring, and individualized treatment targets (ADA Standards of Care).